Krystal Biotech (KRYS) Cash from Financing Activities (2016 - 2026)

Krystal Biotech's Cash from Financing Activities history runs 11 years deep, the most recent figure standing at -$10.5 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 16.1% year-over-year to -$10.5 million; the TTM figure through Mar 2026 stood at $10.7 million (up 170.16% YoY), while the FY2025 annual figure was $8.7 million, down 67.78% from the prior year.
• Cash from Financing Activities came in at -$10.5 million for Q1 2026 at Krystal Biotech, down from $15.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $185.3 million in Q2 2023 to a low of -$12.5 million in Q1 2025.
• A 5-year average of $15.5 million and a median of $3.1 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 15527.14% in 2022 and sank 217.79% in 2025, its largest moves.
• Krystal Biotech's Cash from Financing Activities stood at $3.1 million in 2022, then decreased by 14.66% to $2.6 million in 2023, then decreased by 7.29% to $2.4 million in 2024, then soared by 545.22% to $15.7 million in 2025, then plunged by 166.76% to -$10.5 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$10.5 million, $15.7 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison